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Background: A study was conducted to evaluate the effectiveness of afoxolaner chewables to control flea populations
in naturally infested dogs in private residences in Tampa FL, USA. Evaluations of on-animal and premises flea burdens,
flea sex structure and fed-unfed premises flea populations were conducted to more accurately assess flea population
dynamics in households.
Methods: Thirty seven naturally flea infested dogs in 23 homes in Tampa, FL were enrolled in the study and treated
with afoxolaner chewables. Chewables (NexGard® Chewables; Merial) were administered according to label directions
by study investigators on study day 0 and once again between study days 28 and 30. Flea infestations on pets were
assessed using visual area thumb counts and premises flea infestations were assessed using intermittent-light flea traps
on days 0, 7, 14, 21, and once between study days 28–30, 40–45, and 54–60.
Results: Within 7 days of administration of afoxolaner chewable tablets, flea counts on dogs were reduced by 99.3 %.
By one month post-treatment, total flea counts on dogs were reduced by 99.9 %, with 97.3 % (36/37) of the dogs being
flea free. Following the second dosing on study day 28–30, total on-dog flea burden was reduced by 100 % on days
40–45 and 54–60. On day 0, the traps collected a geometric mean of 18.2 fleas. Subsequent reductions in emerging flea
populations were 97.7 and 100 % by days 28–30 and 54–60, respectively. There were 515 total fleas (Ctenocephalides
felis felis) collected in the intermittent light flea traps on day 0, and 40.4 % of those fleas displayed visual evidence
of having fed. Seven days after initial treatment, only 13.1 % of the fleas contained blood and by day 14 only
4.9 % of the fleas collected in traps displayed evidence of having fed. On day 0, prior to treatment, 60 % of the
unfed fleas collected in intermittent-light flea traps were females, but by days 28–30, unfed males accounted for
78 % of the population.
Conclusions: This in-home investigation conducted during the summer of 2014 in subtropical Tampa, FL demonstrated
that afoxolaner chewables rapidly and effectively eliminated flea populations in infested dogs and homes.
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Several studies conducted in Tampa, FL (USA) over the
past 15 years have demonstrated that dinotefuran-
pyriproxyfen, fipronil (±, (s)-methoprene), imidacloprid,
indoxacarb, lufenuron (+pyrethrin spray or + nitenpyram
tablets) and selamectin were effective in controlling fleas
on naturally infested dogs and cats and in private resi-
dences within 60 to 90 days, without the need for treat-
ment of premises [1–7]. Premises and on-animal flea
infestations are ultimately being controlled in these
homes because these products prevent flea reproduction,
either killing most newly acquired fleas prior to initi-
ation of egg laying and/or rendering the vast majority of
deposited eggs non-viable [5–7]. Field studies such as
these and other investigations have demonstrated that
flea control likely succeeds or fails based upon a product’s
or combination of products’ ability to effectively limit flea
reproduction [5–7].
Recently, a new orally administered afoxolaner chewable
product was introduced into the flea and tick control mar-
ket [8–11]. Afoxolaner is a member of the isoxazoline
class of compounds and is labeled for the treatment and
prevention of flea infestations and treatment and control
of ticks on dogs. When afoxolaner was administered to
dogs as a single chewable at the minimal effective dose of
2.5 mg/kg it provided 99.9–100 % control of fleas for up
to 36 days [8]. Egg production was also almost completely
inhibited in that study. The combination of excellent
month-long residual adulticide activity and inhibition of
egg production would indicate that afoxolaner chewables
should provide excellent control of natural flea infesta-
tions. The objective of this study was to evaluate the per-
formance of afoxolaner chewables in eliminating natural
flea infestations on dogs in Tampa, FL USA.
The effectiveness of the afoxolaner treatment was
assessed using both premises and on-animal flea popula-
tion estimating techniques. Because investigators admin-
istered products to all dogs, this study eliminated any
potential owner compliance issues.
Methods
Home and pet study inclusion criteria
Through referrals from the Sunshine Animal Hospital,
Tampa, FL and advertisements on CRAIGSLIST®, 26 pri-
vate residences were selected for inclusion in the study
from May 19–May 29, 2014.
Homes and dogs were selected based on the following
criteria: 1) a minimum of five fleas observed in area flea
counts on at least one dog at the residence; 2) a minimum
of five fleas collected in a 16–24 h period in two intermit-
tent light flea traps; 3) one to five healthy, non-fractious
dogs residing at the residence (because no isoxazoline ap-
proved for cats was available at the time of this study,
households with cats were excluded); 4) qualifying dogsspent ≥ 12 h/day in the indoor premises; 5) homeowner’s
willing to participate in the study for at least 2 months; 6)
owners agreeing not use any other topical or premises flea
control products during the study; 7) owners agreeing
not to bring any other dogs into the household for the
duration of the study; 8) no dog in the household was
pregnant or nursing; 9) qualifying dogs ≥ 8 weeks of age
and ≥ 4 lbs; 10) completion of a questionnaire concerning
pet habits, visiting pets, previous flea treatments and per-
sonal observations around their residence concerning
wildlife and feral cats; and 11) no residual flea product was
applied in the previous 30 days.
Animals were client-owned dogs and were handled in
compliance with Merial Institutional Animal Care and
Use Committee and Kansas State IACUC approval
(#3413). Throughout the trial, dogs were housed in their
normal environment. There were no restrictions other
than those normally placed on the pet by the pet-owner.
Treatment groups
Dogs were treated orally with an afoxolaner chewable
(NexGard® Chewables; Merial) according to the label
dosing recommendations. Dogs were weighed on Days −1
or 0 and once between days 28–30 to ensure proper dos-
ing. All dogs in each enrolled household were treated on
day 0 and then once between days 28–30. All treatments
were administered by study investigators. No other topical
or premises flea treatments were used during the study.
There were no restrictions on the animals with regard to
exposure to rain, swimming or movement outdoors. How-
ever, while pet activity was not restricted, it was recorded.
It should be noted that in some homes with multiple dogs,
not all dogs qualified for inclusion in the study (fewer than
5 fleas, resided outdoors, inability to examine, etc.).
However, all qualifying and non-qualifying dogs within
each enrolled household were still administered a weight
appropriate afoxolaner chewable.
This study was conducted without a placebo control
group. While the use of a non-treated group might have
provided a better evaluation of the performance of the
treatment regimen, it is the opinion of these authors that
the massive flea infestations commonly encountered in
Tampa, FL preclude the use of a non-treated group.
Withholding treatment would be detrimental to the
health and welfare of the pets and potentially to humans
in a household.
Flea population assessment
The numbers of adult fleas present in the indoor prem-
ises were assessed using intermittent light traps [1–7, 12,
13]. One trap was placed in each of two rooms for 16 to
24-h. Rooms were selected based on where the pet(s)
spent most of the time or where owners had observed
fleas. Once rooms were selected, the traps were returned
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ing period. Fleas collected on the adhesive pads of the
traps were enumerated and identified by microscopic
observation as to characteristics (e.g.: fed, unfed, gravid)
and as to species. In addition, the sex of fleas collected
on light traps for each counting period, for each house-
hold, was determined.
The flea population on each pet was assessed using a
visual area thumb count methodology [1–7, 14]. Area
counts were performed at five locations on each animal;
dorsal midline, tail head, left lateral, right lateral, and in-
guinal region. Area counts were limited to one minute
per location and conducted by parting the hair against
the lay using both hands until the area was covered.
Maximum number of fleas per zone is capped at 50;
therefore the maximum total area flea counts for a pet is
250. Pet and premises flea counts were conducted ± 1 day
on days 0, 7, 14, 21, then once between days 28–30, 40–45,
and 54–60.
Data analysis
Environmental Control Assessments: Percentage of con-
trol achieved by the flea product was calculated using
Geometric Means (GM) and the following formula:
Day z GM Flea trap Counts ‐ Day y GM Flea trap Countsð Þ
Day z GM Flea trap Counts x 100 ¼ % control
Where z = Day 0
Where y = Days 7, 14, 21, 28–30, 40–45 or 54–60
To determine these geometric means, counts were
transformed to the natural logarithm of (count + 1) for
calculation.
 Sex-Ratio & blood fed assessments of fleas
collected in intermittent light flea traps: Fleas
collected in traps were counted by sex throughout
the study, noting the arithmetic percentages of
unfed male to unfed female fleas. Additionally, an
assessment was conducted of blood fed and unfed
fleas found in the traps. Adhesive sheets were
placed under a dissecting microscope and captured
fleas were examined for visual evidence of having
fed. Determination that a flea had fed (blood
consumed) was made by either observing blood in
the midgut of the flea or more commonly seeing a
droplet or droplets of blood immediately posterior
to the flea on the sticky adhesive of the flea trap [5].
 On-Animal Flea Counts: On-animal flea count
estimates of live adult fleas were transformed to the
natural logarithm of (count + 1) for calculation of
geometric means at each time point. Percent
reduction from the control (Day 0) mean were
calculated using the formula [(C-T)/C] × 100,
where C = geometric mean for the control count(Day 0) and T = geometric mean for the treated
group for each subsequent assessment.
Results
Twenty-six homes were originally enrolled in the study,
but only 23 homes were retained in the study for at least
one month. Data from the three households that were
not maintained in the study for at least 28–30 days were
not included. Two homes were dropped because the
owners moved and another household was removed
from the study because the owners adopted a cat. Thus,
data from twenty-three households were analysed in
these assessments.
In the 23 homes that completed the study, there were
37 qualifying dogs (avg. 17.8 kg; range 2.0–47.3 kg) en-
rolled. On day 0, the dogs received a mean oral dose of
4.09 mg/kg (range 2.59–6.21 mg/kg) afoxolaner. There
were an additional 11 dogs in these homes that did not
qualify for the study because they: had an insufficient
numbers of fleas (<5) on day 0, resided permanently out-
doors, or could not be safely handled by flea team mem-
bers to conduct flea counts. Therefore, there were a
total of 48 dogs in the 23 homes that were treated with
the afoxolaner chewables. In one home the owners re-
ported they had a visitor dog 7 days into the study. That
dog was administered weight appropriate dose of afoxo-
laner chewable the same day.
Of those 37 officially enrolled dogs, four did not
complete the study. Two dogs from the same household
were unavailable beyond days 28–30, because the
owners moved during the second month of the study.
One dog in one household died from canine parvovirus
prior to the day 40–45 count. Another dog (14 year old)
in another household was reported by the owner as having
died from “old age” the week prior to the last visit and was
not available for the last flea count. Owners did not report
the dog’s death to the K-State Flea Team until the team ar-
rived at the home for the final flea count, by that time the
dog had been disposed of by the owners and, therefore, it
was impossible to verify the cause of death.
In one household, 5 days after the administration of
afoxolaner chewable, the owner reported that one dog
was vomiting and had diarrhea. The following day the
owner reported that the dog was doing fine. Then again,
one week after the second treatment the owner reported
that the dog was vomiting and had diarrhea. Again, this
resolved within a day. It is unknown if the afoxolaner
chewable was related to vomiting and diarrhea episodes
5 to 7 days after its administration. No other dogs expe-
rienced any adverse events during the study.
On day 0, the 37 dogs treated with afoxolaner chewables
had a geometric mean of 25.1 (range 6–185) fleas ob-
served in area counts (Table 1). Within 7 days of adminis-
tration of afoxolaner, flea counts were reduced by 99.3 %
Table 1 Geometric mean and percent control of on-animal flea counts in naturally infested homes when dogs were treated with
afoxolaner
Treatment group # dogs day 0 Days post-treatment
Day 0 Day 7 Day 14 Day 21 Days 28–30 Days 40–45 Days 54–60
Afoxolaner1 37 Geomean2 25.12 0.18 0.02 0.06 0.02 0.00 0.00
(Std dev) (37.46) (0.79) (0.17) (0.68) (0.17) (0.00) (0.00)
(Range) (6–185) (0–4) (0–1) (0–4) (0–1) (0–0) (0–0)
% control3 99.28 99.92 99.74 99.92 100.00 100.00
% (#) pets with no fleas 0.0 (0/37) 81.1 (30/37) 97.3 (36/37) 94.6 (35/37) 97.3 (36/37) 100 (34/34) 100 (33/33)
1Dogs were orally administered an afoxolaner chewable (NexGard®; Chewables; Merial, Inc.) on day 0 and once between days 28–30
2Geometric mean numbers of fleas in visual area thumb counts on dogs
3{(Day 0 geometric mean animal area flea counts-day x geometric mean animal area flea counts)/day 0 geometric mean animal area flea counts)} × 100
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counts were reduced by 99.9 %. In addition, 97.3 % (36/37)
of the dogs treated with afoxolaner were flea free within
one month. Following re-administration at one month,
total on-dog flea burden was reduced by 100 % on days
40–45 and 54–60 (Table 1).
During the entire 2 month study, 739 fleas were
trapped in the 23 residences using intermittent-light
traps and all were identified as Ctenocephalides felis felis,
the cat flea. On day 0, the traps collected a geometric
mean of 18.2 (range 5–86) fleas (Table 2). Reductions in
emerging flea populations were 97.7 and 100 % by days
28–30 and 54–60, respectively (Table 2).
Of particular interest was that 40.4 % of the 515 fleas
collected in the intermittent light flea traps on day 0, i.e.
prior to treatment, displayed visual evidence of having
fed. However, none of the fleas collected throughout the
entire study appeared to have undergone prolonged
feeding as evidenced by the lack of abdominal enlarge-
ment and none of the females were large enough to have
reached reproductive capacity.
Following treatment there was not only a reduction in
numbers of fleas, but also the percentage of fleas con-
taining blood collected on the traps. Seven days after
treatment only 13.1 % of the fleas contained blood and
by day 14 only 4.9 % displayed evidence of having fed.
When all homes were averaged together there was a
shift over time in the ratio of unfed female to unfed male
fleas collected in premises flea traps. On day 0, prior toTable 2 Geometric mean and percent control of fleas recovered in
treated with afoxolaner
Treatment group # homes completing study Days post-
Day 0




1Dogs were orally administered an afoxolaner chewable (NexGard®; Chewables; Me
2Geometric mean numbers of fleas recovered in two intermittent light flea traps pla
3(Day 0 geometric mean trap flea counts-day x geometric mean trap flea counts)/dtreatment, 40 % of the unfed fleas collected in
intermittent-light flea traps were males. Then on days 7,
14, 21, and 28–30, males accounted for 61, 26, 72 and
78 %, respectively. The percentage of male fleas on days
40–45 was 33 %, but that percentage represents only 2
of 6 fleas from a single home.
The client interviews conducted before homes were
entered into the study clearly showed that reservoir
hosts for C. felis were commonly observed by pet
owners. A majority of pet owners said they had seen
opossums (65.2 %; 15/23), raccoons (65.2 %; 15/23) and/or
feral cats (91.3 %; 21/23) in their yards.Discussion
Previous evaluations of the effectiveness of topical and
systemic flea products to control natural flea infestations
in homes and on pets in Tampa, FL have demonstrated
that reductions in total pet flea burdens are almost
always less than 100 % following 60 to 90 days of treat-
ment [1–7]. However, in this study afoxolaner chewables
achieved 100 % reduction in on-animal flea populations
within 40–45 days after two regular monthly administra-
tions. The area count technique used in this and previous
in-home investigations has been shown to detect an aver-
age of 23.5 % of the total pet flea burden [14]. Therefore,
average pretreatment total body flea burdens on dogs were
estimated to be 107 fleas based on the geometric mean
area count of 25.1.premises flea traps in naturally infested homes when dogs were
Treatment1
Day 7 Day 14 Day 21 Days 28–30 Days 40–45 Days 54–60
1.69 0.72 1.09 0.43 0.09 0.00
(6.26) (4.65) (8.87) (0.89) (1.28) (0.00)
(0–26) (0–17) (0–43) (0–3) (0–6) (0–0)
90.73 96.04 93.99 97.66 99.49 100.00
rial, Inc.) on day 0 and once between days 28–30
ced in homes
ay 0 geometric mean trap flea counts)} × 100
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97.3 % (36/37) of the dogs were free of fleas. While
infestation pressure can vary from year to year it is
interesting to note that in two previous investigations
in Tampa using this same study design, percent of flea
free dogs at similar time frames post-treatment were
much lower. At 14 days post-treatment indoxacarb,
dinotefuran/pyriproxyfen/permethrin and fipronil (s)-
methoprene topical spot-ons had only achieved 71.4 %
[6], 20 % [7] and 22.2 % [7] flea free status on treated
pets, respectively [6, 7].
It has been previously documented that actively repro-
ducing Ctenocephalides felis felis remain resident upon
their host and rarely leave unless forced off by insecti-
cide application or host grooming [15]. This permanent
association of reproducing fleas with their host is the
key factor that allows topical and systemic flea control
products to achieve success in eliminating an existing
in-home infestation [5–7, 16]. As immature flea life
stages continue to develop in the premises, the biomass
is ultimately exhausted because effective residual flea
products prevent new viable eggs from being deposited
[5–7, 16]. While the above is certainly true, recent
investigations have brought more refinement to our
understanding of this parasite-host interplay. A previ-
ous in-home field investigation determined that prior
to on-animal treatment 34.4 % of fleas collected in
intermittent-light flea traps contained small quantities
of blood [5]. Similarly, in this current study 40.4 % of
the fleas collected in the intermittent-light flea traps on
day 0 displayed visible evidence of having fed. Several
factors have been postulated to account for the pres-
ence of blood in fleas collected in premises traps such
as pet grooming activity, hyper-excitation of fleas due
to application of an insecticide, or some of the fleas
may have fed upon humans in the household. Another
possibility is that before establishing themselves as per-
manent ectoparasites, there may be a period of time
when a percentage of fleas display inter-host move-
ment. This movement between hosts was previously
described by Rust (1994) [17], and more recently, an-
other study further demonstrated this inter-host move-
ment of newly acquired non-reproducing C felis [18].
In that study, cats were infested with C. felis and then
15 min later co-mingled with non-infested cats [18].
Twenty-four hours later it was determined that 20 % of
the fleas transferred from the infested to the previously
non-infested cats [18]. However, when cats were
infested with fleas and held for 48 h before co-mingling
with non-infested cats, only 3.7 % of the fleas trans-
ferred. In a previous field study only 9 of 771 (1.17 %)
fleas collected in the intermittent-light flea traps were
considered engorged or to have fed long enough to
have potentially reached reproductive status [5] and inthe current study none of 515 (0.00 %) fleas collected
in the traps displayed evidence of prolonged feeding
(engorged) or of having achieved reproductive status.
These data indicate that prior to C. felis achieving re-
productive status (24–48 h), a percentage of the fleas
may feed for short durations of time and move on and
off the host and that inter-host movement is occurring.
Additionally, these data also further support that once
reproduction is initiated, movement of fleas on and off
the host and inter-host movement is quite limited.
In the context of the current study, it is important to
note that there was a reduction in percentage of fed fleas
recovered in the flea traps following treatment from
40.4 % prior to treatment, down to 4.9 % on day 14. This
reduction in percent of fed fleas recovered in traps fol-
lowing treatment may indicate that most newly emerged
fleas jumping on and then feeding on treated dogs were
either dying before jumping back off the dogs or were
too moribund to jump towards the intermittent light
traps. These data, coupled with the high on-animal flea
efficacy and percent flea free dogs, demonstrates that
afoxolaner chewables provide rapid residual flea kill
under field conditions.
Another potential indicator of rapid residual speed of
kill of afoxolaner under field conditions can be observed
in the single red-line home observed in this study. A
“red-line” home is a household in which there is a 20 %
or greater increase in emergence flea trap counts, over
day 0 trap counts, within one month after treatment [5,
16]. A red-line home indicates that at the time of treat-
ment the flea population is either in a rapid growth
phase or development and emergence has been delayed
by environmental conditions (i.e.: a period of cool ambi-
ent temperatures) [5]. In the one red-line home ob-
served in this study, the premises intermittent-light flea
traps counts went from 15 on day 0 to 16 fleas, 17 fleas
and then 43 fleas on days 7, 14 and 21, respectively.
However, the flea counts on the dog in that household
started high at 70 on day 0, but were 0, 0 and 4 on days
7, 14 and 21, respectively, falling to 0 again for the
remaining assessments. These data demonstrate that
even when there was an escalating emerging flea popula-
tion, flea numbers on the treated dog did not escalate
accordingly. A different measure of product performance
entails the evaluation of gender structure of newly
emerged (unfed) fleas collected in intermittent-light
traps in these homes [5]. Unfed fleas are used in this
analysis so that the gender of only the newly emerging
fleas is being assessed. While most insect species exhibit
protrandry (males tend to emerge before females), C.
felis belong to a much smaller group that exhibits pro-
togny (females tend to develop before males) [19]. The
first fleas to emerge from a cohort of eggs are females,
followed by both males and females and then lastly
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strated that if flea reproduction is inhibited by insecticidal
and/or insect growth regulator treatments administered to
a pet, then a sex shift in premises flea population takes
place overtime from a female dominated population to-
wards a more male dominated population [5]. In this
current study, only 40 % of the unfed fleas collected on day
0 were male, whereas by 28–30 days following treatment
78 % of the unfed fleas collected were male. This was a
clear and rapid sex shift indicative of a dramatic reduction,
if not complete cessation, of flea reproduction.
A challenge for many pet owners is the flea reinfesta-
tion pressure from flea infested urban wildlife as well as
dogs and cats. In North America, feral cats and urban
wildlife such as opossums and raccoons can be infested
with C. felis, which can deposit eggs and contaminate
protected outdoor premises locations [20]. Given the po-
tential for reinfestation, it should be noted that 91.3 % of
dog owners in this study had seen feral cats and 65.2 %
also reported observing either opossums or raccoons in
their yards. Given that such a large percentage of
owners’ yards are frequented by potentially flea infested
animals, it is reasonable to assume that these dogs are
under frequent infestation pressure.
It has been documented that opossums and feral cats
living in urban areas can be infested with C. felis infected
with Rickettsia felis [21–23]. It has been established that
Bartonella henselae is transmitted among cats by C. felis
and that feral cats may be infected with Bartonella spp.
[23]. Recently it was demonstrated that raccoons and
feral cats in the state of Georgia (USA) had similar rates
of B. henselae infection as demonstrated by PCR of
blood samples [24]. The presence of raccoons, opossums
and feral cats in these pet owners’ yards is also important
as it relates to the potential transmission of pathogenic
Rickettsia felis and Bartonella spp. to dogs, cats and
humans [21–24]. Therefore, a recommendation of con-
tinual flea control, in such situations seems prudent
not only to prevent re-infestations but also to possibly
interdict disease transmission.
Conclusions
This in-home investigation conducted during the sum-
mer of 2014 in subtropical Tampa, FL demonstrated that
afoxolaner chewables rapidly and effectively eliminated
heavy flea burdens from dogs and in flea-infested homes.
On dog flea burdens were near zero within one week,
and completely eliminated fleas from all dogs assessed in
the study within 6 weeks. The observed sex shift of
emerging fleas from predominately female to male and
the rapid elimination of emerging fleas in these homes
would indicate that afoxolaner greatly reduced, if not
completely eliminated, viable flea reproduction.
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